Pharma News

A study recently accepted for publication in The Journal of Clinical Investigation describes a new and effective therapy to treat glioblastoma: the concomitant use of ADI-PEG20 together with focal brain radiotherapy. This double treatment completely eliminated the tumour in the animal models used in the study. This study was carried out by researchers from the Institute of Biomedicine of Seville: Dr. Manuel Sarmiento Soto, Dr. Juan García Revilla, and Dr. José Luis Venero, in collaboration with Dr. Nabil Hajji and Dr. Nel Syed of Imperial College London.

There is substantial interest regarding the understanding and designing of nanoengineered bacteria to combat various fatal cancerous diseases. However, conventional nanotechnological approaches adopt genetic manipulation for attenuating and improving the efficacy of bacteria. In addition, complicated chemical reactions were essential in the previous approaches.

Galderma and Taro Pharmaceutical Industries Ltd announced they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv® brand.

The Sistema Group company Binnopharm Group, one of the leading pharmaceutical production companies in Russia via its affiliate Joint Stock Company Alium, and Dr. Reddys Laboratories Ltd an integrated global pharmaceutical company, today announced the signing of a deal that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr. Reddys in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solution for infusions and eye drops.

Strides Pharma Science Limited announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Amantadine Hydrochloride Softgel Capsules USP, 100 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Symmetrel Capsules, 100 mg, of Endo Pharmaceuticals, Inc (Endo).

NIAB discover potential biomarker, NS 1 protein for Japanese encephalitis virus. Non-Structural 1 protein, a potential diagnostic biomarker for Japanese encephalitis virus. A diagnostic biomarker refers to a biological parameter that aids the diagnosis of a disease and may serve in determining disease progression or success of treatment.

Novartis to get approval for import and marketing of Dabrafenib, anticancer medicine for additonal indication from CDSCO. Subject Expert committee recommends CDSCO for grant of permission to import and marketing of Dabrafenib capsules 50 mg and 75 mg.

Novartis presented their proposal for import and marketing of the drug Dabrafenib capsules 50 mg and 75 mg for an additional indication, along with justification for clinical trial waiver before the committee.

Government eases the norms of manufacturing, stocking, sale or distribution of new drugs under phase III clinical trials, for the treatment of Covid-19 and related diseases. The provision is made to stock the drugs with a condition that it will sell the new drug only after obtaining permission as per the regulations.

Certain sections of the media have falsely linked again Giloy/Guduchi to liver damage. The Ministry of Ayush reiterates that Giloy/Gudduchi (Tinospora cordifolia) is safe and as per available data, Guduchi does not produce any toxic effect.